Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;4(6):387-92.
doi: 10.2217/cns.15.22. Epub 2015 Oct 26.

Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review

Denis Migliorini  1 , Sven Haller  2 , Doron Merkler  3 , Angela Pugliesi-Rinaldi  1 , Avinash Koka  4 , Karl Schaller  4 , Beatrice Leemann  1 , Pierre-Yves Dietrich  1
Affiliations
Review

Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review

Denis Migliorini et al. CNS Oncol. 2015.

Abstract

Hemangioblastoma is a rare benign neoplasm, accounting for less than 2% of all primitive brain tumors. It may arise sporadically in a solitary form, or associated with Von Hippel-Lindau (VHL) disease with multiple tumors. Surgery is the mainstay treatment, but management is challenging in case of recurrent and/or multiple tumors. VHL protein is defective in both forms of hemangioblastoma, leading to the accumulation of hypoxia-inducible factor, stimulating angiogenesis via VEGF and PDGF mainly. Here, we report a 37-year-old woman's case with recurrent and rapidly progressive VHL-associated hemangioblastomas, causing severe disability. She was treated 24 months with pazopanib, a multityrosine kinase inhibitor (TKI) targeting VEGF and PDGF-β pathways. Despite moderate radiological changes, progressive improvement in her clinical condition persisting over 3 years was observed. Inhibiting angiogenesis is a therapeutic option that may improve the quality of life and the autonomy of VHL patients disabled with multiple hemangioblastomas.

Keywords: Von Hippel–Lindau disease; hemangioblastoma; pazopanib.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Illustrative examples of the hemangioblastomas arising from 2002 to 2012.
<b>Figure 2.</b>
Figure 2.. Pathology description.
Hematoxylin and Eosin (H/E) staining (A) or immunostaining (B–D) were performed on formalin-fixed and paraffin-embedded histological sections. (A) Tumor proliferation is characterized by stromal cells situated in a dense capillary network. (B) Immunostaining demonstrates strong and diffuse S100 positivity in stroma cells. (C) The presence of a dense capillary network is illustrated by the endothelial marker CD34 staining. (D) Only few proliferating cells are detected by immunostaining for Ki67. Scale bars for A–C: 100 μm, for D: 200 μm.
<b>Figure 3.</b>
Figure 3.. C3-C4 target lesion evolution under therapy.
Intramedullary contrast-enhancing lesion at the level of C3–C4 (white arrow) with associated myelopathy (A), February 2012 baseline MRI (sag T1Gd), which remains stable at follow-up (9 months later (B) and 15 months later (C)). Note the presence of the other known lesion at the level of C1 (gray arrow), the postoperative changes at the level of C6 (only partially displayed), and the anterior spinal artery (blue arrow).
See this image and copyright information in PMC

References

    1. Li L, Kaelin WG., Jr New insights into the biology of renal cell carcinoma. Hematol. Oncol. Clin. North Am. 2011;25(4):667–686. - PMC - PubMed

    2. • Focuses primarily on the most common form of RCC, clear-cell renal carcinoma, noting some recent advances in the other histologic subtypes.

    1. Kaelin WG., Jr New cancer targets emerging from studies of the Von Hippel–Lindau tumor suppressor protein. Ann. NY Acad. Sci. 2010;1210:1–7. - PMC - PubMed

    2. • Highlights the various targetable pathways in VHL disease.

    1. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am. J. Pathol. 1998;153(1):25–29. - PMC - PubMed
    1. Kim BY, Jonasch E, Mccutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel–Lindau disease: case report. Target Oncol. 2012;7(2):145–149. - PMC - PubMed

    2. •• Report of oral pazopanib resulting in significant neurologic improvement and radiologic tumor volume reduction in CNS hemangioblastomas associated with VHL disease.

    1. Lonser RR, Glenn GM, Walther M, et al. Von Hippel–Lindau disease. Lancet. 2003;361(9374):2059–2067. - PubMed

    2. • This article provides an overview of the clinical aspects, management and treatment options for von Hippel–Lindau disease.

MeSH terms

LinkOut - more resources